Search: WFRF:(Johansson Ann Charlotte) >
Docetaxel, trastuzu...
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer : results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
-
Bergh, Jonas C. S. (author)
-
- Andersson, Anne, 1966- (author)
- Umeå universitet,Onkologi
-
Bjohle, Judith (author)
-
show more...
-
Bosch, Ana (author)
-
Carlsson, Lena (author)
-
- Dreifaldt, Ann Charlotte, 1964- (author)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
Einbeigi, Zakaria (author)
-
Fredholm, Hanna (author)
-
Isaksson-Friman, Erika (author)
-
Foukakis, Theodoros (author)
-
Elinder, Ellinor (author)
-
Hellstrom, Mats (author)
-
Johansson, Hemming (author)
-
Lekberg, Tobias (author)
-
Lindman, Henrik (author)
-
Maes, Claudia (author)
-
Brandberg, Yvonne (author)
-
Hatschek, Thomas (author)
-
show less...
-
(creator_code:org_t)
- American Society of Clinical Oncology, 2019
- 2019
- English.
-
In: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 37:15, s. 501-501
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Neoadjuvant therapy produces high rates of pathological complete response (pCR) and is the standard of care in HER2 positive breast cancer; however, the optimal treatment regimen remains to be established. Methods: In this randomized phase II study patients ≥18 years with HER2 positive breast cancer > 20mm or verified lymph node metastases were randomized to 6 courses of docetaxel, trastuzumab and pertuzumab (DTP, group A) or trastuzumab emtansine (T-DM1, group B), q 21 days. The protocol allowed switch to the competing treatment upon lack of response or drug-related severe toxicity. Patients received postoperative epirubicin+cyclophosphamide, trastuzumab for a total of one year and endocrine therapy. Accrual was completed in October 2018 after randomization of 202 patients, data on pCR were available for 190 at the time for this abstract submission. Median age, 52 years (26-74), menopausal status, histological type and grade were well balanced between the treatment groups. 62.6% of the tumors were hormone receptor (HR) positive. Results: Primary endpoint was pathological objective response. 190 patients completed the protocol-specified preoperative treatment. pCR was achieved in 45.3% of patients, 46.4% in patients treated with DTP and 44.1% with T-DM1 (chi-sq., p = 0.75). In HR-positive tumors, pCR was obtained in 35.3% of patients, 35.9% in group A vs. 34.6% in group B (p = 0.87); in HR-negative tumors, the overall pCR rate was 62.0%, 66.7% in group A vs. 57.9% in group B (p = 0.45). Severe (grade 3/4) toxicity was reported at 68 occasions related to DTP, compared with 16 related to T-DM1, 26 vs. 3 caused by febrile neutropenia. Significantly better quality of life was reported by patients treated with T-DM1. Conclusions: Our data on TDM-1 demonstrates similar efficacy and less toxicity, in particular for patients with HER2 and HR positive cancers, being a potential new standard for neoadjuvant therapy. Clinical trial information: NCT02568839.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- vet (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Bergh, Jonas C. ...
-
Andersson, Anne, ...
-
Bjohle, Judith
-
Bosch, Ana
-
Carlsson, Lena
-
Dreifaldt, Ann C ...
-
show more...
-
Einbeigi, Zakari ...
-
Fredholm, Hanna
-
Isaksson-Friman, ...
-
Foukakis, Theodo ...
-
Elinder, Ellinor
-
Hellstrom, Mats
-
Johansson, Hemmi ...
-
Lekberg, Tobias
-
Lindman, Henrik
-
Maes, Claudia
-
Brandberg, Yvonn ...
-
Hatschek, Thomas
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Journal of Clini ...
- By the university
-
Umeå University
-
Örebro University
-
Karolinska Institutet